These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31294133)

  • 1. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
    Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
    Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
    Bolton EM; Lynch T
    BJU Int; 2018 Sep; 122(3):371-383. PubMed ID: 29438592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eligard: leuprolide acetate in a novel sustained-release delivery system.
    Sartor O
    Urology; 2003 Feb; 61(2 Suppl 1):25-31. PubMed ID: 12667884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.
    Heyns CF; Simonin MP; Grosgurin P; Schall R; Porchet HC;
    BJU Int; 2003 Aug; 92(3):226-31. PubMed ID: 12887472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
    Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
    Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
    Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Goserelin versus leuprolide in the chemical castration of patients with prostate cancer.
    Dias Silva É; Ferreira U; Matheus W; Faria EF; Silva GD; Saito M; de Souza AA; Laranjo A; Clark O; Magna LA; Castilho LN; Reis LO
    Int Urol Nephrol; 2012 Aug; 44(4):1039-44. PubMed ID: 22315155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
    Koh Y; Kawashima A; Ujike T; Nagahara A; Fujita K; Kiuchi H; Imamura R; Miyagawa Y; Nonomura N; Uemura M
    Anticancer Drugs; 2020 Nov; 31(10):1099-1102. PubMed ID: 32804697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.
    Østergren PB; Kistorp C; Fode M; Henderson J; Bennedbæk FN; Faber J; Sønksen J
    J Urol; 2017 Jun; 197(6):1441-1447. PubMed ID: 27939836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Change of the LHRH analogue in progressive castration-refractory prostate cancer].
    Heidenreich A; Porres D; Epplen R; van Erps T; Pfister D
    Urologe A; 2012 Sep; 51(9):1282-7. PubMed ID: 22733398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated With Diverse Chemical Castrations.
    Reis LO; Denardi F; Faria EF; Silva ED
    Am J Mens Health; 2015 Sep; 9(5):430-4. PubMed ID: 25294865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety.
    Raja T; Sud R; Addla S; Sarkar KK; Sridhar PS; Talreja V; Jain M; Patil K
    Indian J Cancer; 2022 Mar; 59(Supplement):S142-S159. PubMed ID: 35343198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients.
    Novara G; Galfano A; Secco S; Ficarra V; Artibani W
    Urol Int; 2009; 82(3):249-55. PubMed ID: 19440008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.
    Breul J; Lundström E; Purcea D; Venetz WP; Cabri P; Dutailly P; Goldfischer ER
    Adv Ther; 2017 Feb; 34(2):513-523. PubMed ID: 28028737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triptorelin in the management of prostate cancer.
    Ploussard G; Mongiat-Artus P
    Future Oncol; 2013 Jan; 9(1):93-102. PubMed ID: 23252566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
    Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
    Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.